Activity

Filter

Cancel
Date Panel Item Activity
7 actions
Genetic Epilepsy v0.2161 ATP6V0A1 Elena Savva Phenotypes for gene: ATP6V0A1 were changed from Developmental and epileptic encephalopathy 104 MIM#619970; Neurodevelopmental disorder with epilepsy and brain atrophy MIM#619971 to Developmental and epileptic encephalopathy 104 MIM#619970; Neurodevelopmental disorder with epilepsy and brain atrophy MIM#619971
Genetic Epilepsy v0.2161 ATP6V0A1 Elena Savva Phenotypes for gene: ATP6V0A1 were changed from Neurodevelopmental disorder, MONDO:0700092, ATP6V0A1-associated to Developmental and epileptic encephalopathy 104 MIM#619970; Neurodevelopmental disorder with epilepsy and brain atrophy MIM#619971
Genetic Epilepsy v0.1604 ATP6V0A1 Bryony Thompson Marked gene: ATP6V0A1 as ready
Genetic Epilepsy v0.1604 ATP6V0A1 Bryony Thompson Gene: atp6v0a1 has been classified as Green List (High Evidence).
Genetic Epilepsy v0.1604 ATP6V0A1 Bryony Thompson Classified gene: ATP6V0A1 as Green List (high evidence)
Genetic Epilepsy v0.1604 ATP6V0A1 Bryony Thompson Gene: atp6v0a1 has been classified as Green List (High Evidence).
Genetic Epilepsy v0.1456 ATP6V0A1 Chern Lim gene: ATP6V0A1 was added
gene: ATP6V0A1 was added to Genetic Epilepsy. Sources: Literature
Mode of inheritance for gene: ATP6V0A1 was set to BOTH monoallelic and biallelic, autosomal or pseudoautosomal
Publications for gene: ATP6V0A1 were set to PMID:34909687
Phenotypes for gene: ATP6V0A1 were set to Neurodevelopmental disorder, MONDO:0700092, ATP6V0A1-associated
Review for gene: ATP6V0A1 was set to GREEN
gene: ATP6V0A1 was marked as current diagnostic
Added comment: PMID: 34909687
- 17 individuals from 14 unrelated families: 5 affected individuals with biallelic variants, presented with early-onset progressive myoclonus epilepsy with ataxia; 12 individuals carried de novo missense variants and showed severe developmental and epileptic encephalopathy.
- The mean age of onset was 11.8+/-7.5 years for individuals carrying the compound heterozygous variants and 5.8+/-4.2 months for individuals with the de novo variants.
Sources: Literature